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Abstract
Objective: Diffusion tensor imaging (DTI) is sensitive to white matter tract
pathology. A core signature involving the corticospinal tracts (CSTs) has been
identified in amyotrophic lateral sclerosis (ALS). Raised neurofilament light
chain protein (NfL) in cerebrospinal fluid (CSF) is thought to reflect axonal
damage in a range of neurological disorders. The relationship between these
two measures was explored. Methods: CSF and serum NfL concentrations and
DTI acquired at 3 Tesla on the same day were obtained from ALS patients
(n = 25 CSF, 40 serum) and healthy, age-similar controls (n = 17 CSF, 25
serum). Within-group correlations between NfL and DTI measures of micro-
structural integrity in major white matter tracts (CSTs, superior longitudinal
fasciculi [SLF], and corpus callosum) were performed using tract-based spatial
statistics. Results: NfL levels were higher in patients compared to controls. CSF
levels correlated with clinical upper motor neuron burden and rate of disease
progression. Higher NfL levels were significantly associated with lower DTI
fractional anisotropy and increased radial diffusivity in the CSTs of ALS
patients, but not in controls. Interpretation: Elevated CSF and serum NfL is, in
part, a result of CST degeneration in ALS. This highlights the wider potential
for combining neurochemical and neuroimaging-based biomarkers in neurolog-
ical disease.
Introduction
Neurofilament in cerebrospinal fluid (CSF) and serum
has emerged as a much-needed candidate biomarker for
the fatal adult neurodegenerative disorder amyotrophic
lateral sclerosis (ALS).1 The neurofilament light chain
protein (NfL) is the main structural constituent of the
neuroaxonal cytoskeleton and mainly found in large,
myelinated axons. Elevated NfL CSF concentrations seem
likely to reflect axonal loss. Increased CSF NfL has been
previously reported in ALS,2–4 and levels found to corre-
late with measures of disease severity and progression in
ALS.5,6
In addition to neurochemical markers, measures
derived from noninvasive magnetic resonance diffusion
tensor imaging (DTI), such as fractional anisotropy (FA)
and radial diffusivity (RD) have been found to be sensi-
tive to microstructural white matter alterations. While the
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former metric represents the degree of anisotropy of the
diffusion of water molecules in axons and decreased FA is
a frequent correlate of brain tissue injury, RD is a mea-
sure of diffusion perpendicular to the axon, and therefore
commonly linked to the microstructure of myelin.7 Spe-
cifically, in ALS, a strong DTI white matter signature
involving the corticospinal tracts (CSTs) and motor fibers
in the corpus callosum (CC) has been consistently identi-
fied at group level,8,9 and FA and RD measures in the
CSTs were found to correlate with upper motor neuron
(UMN) score and progression rate.10,11
While numerous studies concluded that NfL or MRI
measures show promise as biomarkers for diagnosis or as
predictors of disease progression in different neurological
disorders, to date there has been little attempt to directly
relate the two.
Gaining insight in how and where in the brain these
different measures relate to each other in health and dis-
ease may assist the development of improved, combined
biomarker panels. Therefore, we investigated the relation-
ship between CSF NfL levels and DTI measures of white
matter microstructural integrity in a cohort of ALS
patients and healthy controls, and furthermore attempted
to correlate neurochemical data with clinical scores in the
patient group. We repeated the analyses for serum NfL
concentrations, for which there was a large cohort avail-
able with both measures.
Methods
Participants
Prevalent and incident cases of ALS from a large tertiary
referral clinic were offered participation in Phase 1 of
the Oxford Study for Biomarkers in MND (“BioMOx”)
between 2009 and 2013. Ethical approval for all proce-
dures was obtained in advance (South Central Oxford
Ethics Committee: 08/H0605/85), with written informed
consent obtained from all participants. All patients in
this study were apparently sporadic, that is, reporting no
family history of ALS or frontotemporal dementia
(FTD), and diagnosed by one of two experienced neurol-
ogists (M. R. T., K. T.) according to standard criteria.
The revised ALS Functional Rating Scale (ALSFRS-R)
was used to assess disability on the day of study (M. R.
T.). Disease duration was calculated from symptom
onset to scan date in months, and the rate of progres-
sion was determined as (48  ALSFRS-R)/disease dura-
tion. A clinical UMN clinical burden score of 15
comprised the number of pathologically brisk reflexes
(abnormal glabellar tap response [1], facial jerk [1], jaw
jerk [1], biceps [2], triceps [2], finger [2], knee [2],
ankle [2] reflexes, and extensor plantar responses [2]).
Determination of CSF and serum NfL
concentrations
CSF and serum samples were processed within 1 h of extrac-
tion and on the same day as the MRI (M. R. T.). Samples
were centrifuged, aliquoted, and stored in polypropylene
tubes at 80°C until analysis. An electrochemiluminescence
enzyme-linked immunosorbent assay (ELISA) was used to
quantify NfL as previously described.12
MRI acquisition
Scans were performed at the Oxford Centre for Clinical
Magnetic Resonance (OCMR) using 3 T Siemens Trio
scanner (Siemens AG, Erlangen, Germany) with a 12-
channel head coil. For each subject T1-weighted images
were obtained using a 3D Magnetization Prepared-Rapid
Acquisition Gradient Echo (MP-RAGE) sequence (192
axial slices, flip angle: 8°, 1 9 1 9 1 mm3 voxel size, TE/
TR/TI = 4.7/2040/900 msec). Acquisition time for the
MP-RAGE image was 6 min. Whole-brain DTI images
were acquired using an echoplanar imaging sequence (60
isotropic directions; b value = 1000 sec/mm2; echo time/
repetition time = 94/10,000 msec; 2 9 2 9 2 mm3 voxel
size; 65 slices). In addition, four images without diffusion
weighting were acquired. Furthermore, a field map was
acquired using a gradient echo imaging sequence
(2 9 2 9 2 mm3 voxel size; 65 slices; echo time 1/echo
time 2/repetition time = 5.19/7.65/655 msec) to account
for distortions caused by field inhomogeneities.
MRI analysis
All images were analyzed using tools from the FMRIB
Software Library (FSL; FMRIB, Oxford, UK; www.fsl.fmri-
b.ox.ac.uk/fsl/fslwiki/).
DTI general pre-processing
Each subject’s DTI scans were corrected for head motion
and eddy currents and then brain-extracted to remove
any non-brain voxels. To correct for B0 inhomogeneities
and unwarp scans, field map correction was performed
with FUGUE. FA, mean diffusivity (MD), axial diffusivity
(AD, eigenvector L1), and L2 and L3 maps were created
using DTIFIT by applying a diffusion tensor model to
each voxel. RD maps were created by averaging the L2
and L3 maps (RD = (L2 + L3)/2).
DTI tract-based spatial statistics (TBSS)
preprocessing
All individual FA images of all subjects were nonlinearly
registered to a standard FA template (http://fsl.fmrib.ox.ac.
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uk/fsl/fslwiki/FMRIB58_FA), and then averaged to create a
study-specific template to which each subject’s FA map
was then nonlinearly registered. Next, the mean FA image
was created and thinned to create a mean FA skeleton,
which represents the centers of all tracts common to the
group. Each subject’s aligned FA data were then projected
onto this skeleton. The same operations that were used to
register the individual FA images to the study-specific tem-
plate and project FA values onto the mean FA skeleton
were subsequently applied to the individual MD, L1, and
RD images.
Statistical analyses
The Juelich Histological Atlas was used to produce masks
of the left and right CST, callosal body (CC), and superior
longitudinal fascicle (SLF) in Montreal Neurological Insti-
tute (MNI) standard space. The CST and CC are obvious
a priori region-of-interest (ROI) choices in ALS. The SLF
was chosen based on previously published studies report-
ing involvement of extra-motor tracts in ALS. For the
TBSS analysis, where the final ROI results from the inter-
section of the atlas-based masks and the mean FA skeleton
mask, the left and right CST and CC masks were threshol-
ded at “45” and the left and right SLF masks thresholded
at “10” (as described previously in Menke et al.11).
Voxel-wise General Linear Model (GLM) was applied
using permutation-based non-parametric testing to
regress CSF and serum NfL concentrations with the pre-
processed TBSS images separately in patients and controls
(controlling for age by inclusion as a covariate of no
interest). Results were considered significant for P < 0.05,
after correction for multiple comparisons (family wise
error, FWE) within each region of interest, using the
threshold-free cluster enhancement (TFCE) approach.13
CSF and serum NfL concentrations were separately
correlated with age in both groups, and with UMN score
and progression rate in the ALS group (Spearman
correlation implemented in IBM SPSS Statistics 21; IBM
Corporation, Armonk, New York, US).
Results
Participants
Twenty-five patients and 17 healthy, age-matched controls
with CSF NfL levels and MRI data obtained on the same
day were available for analysis (from a total of 72 patients
and 35 controls enrolled in the wider BioMOx study).
Paired serum samples and MRI data were available for a
larger cohort of 40 patients and 25 controls. Participant
features are summarized in Table 1.
CSF and serum NfL concentrations
In both groups, CSF and serum NfL concentrations were
significantly correlated (patients: q = 0.642, P = 0.001;
controls: q = 0.677, P = 0.004).
Mean CSF NfL levels were significantly higher in
patients (7118  4879 pg/mL) versus controls
(663  464 pg/mL; P < 0.0001, Independent-Samples
Mann–Whitney U Test). CSF NfL concentration was posi-
tively correlated with age (q = 0.800, P < 0.0001) in con-
trols, but not in patients. In patients, CSF NfL levels
correlated positively with UMN score (q = 0.459,
P = 0.021), and progression rate (q = 0.780, P < 0.0001)
(Fig. 1).
As in the overall sample patients and controls differed
significantly with respect to age (P = 0.048) and gender
distribution, we also compared CSF NfL levels between a
closely age-matched subset of 15 patients (seven female,
eight male; mean age = 56  10 years) and 15 controls
(eight female, seven male; mean age = 55  12 years;
P = 0.909). The results of the group comparison
Table 1. Summary of study participant features (mean values and standard deviation in parentheses).
Group Age (years) Sex
Site of symptom
onset
Disease duration
(months) UMN score ALSFRS-R Rate of progression
CSF ALS 61.5 (11.2) 7F:18M Bulbar 6
R limb 11
L limb 8
34.8 (29.7) 10.3 (3.8) 35.2 (5.5) 0.68 (0.78)
Controls 54.3 (11.3) 10F:7M n/a n/a n/a n/a n/a
Serum ALS 60.2 (11.5) 13F:27M Bulbar 7
R limb 19
L limb 13
Both legs 1
39.8 (31.1) 9.8 (4.0) 34.8 (5.6) 0.56 (0.65)
Controls 52.4 (12.6) 15F:10M n/a n/a n/a n/a n/a
UMN, upper motor neuron; ALSFRS-R, revised ALS Functional Rating Scale; CSF, cerebrospinal fluid; ALS, amyotrophic lateral sclerosis; F, female;
M, male.
750 ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
NFL and DTI in ALS R. A. L. Menke et al.
remained qualitatively unchanged for this smaller cohort;
with significantly higher mean CSF NfL level in patients
(7446  5392 pg/mL) versus controls (700  482 pg/mL;
P < 0.0001, Independent-Samples Mann–Whitney U
Test).
Mean serum NfL level was also significantly higher in
patients (97  90 pg/mL) versus controls (30  31 pg/
mL; P < 0.0001, Independent-Samples Mann–Whitney U
Test). Serum NfL concentration was also positively corre-
lated with age (q = 0.643, P = 0.001) in controls, and
correlated positively with UMN score (q = 0.341,
P = 0.031), and progression rate (q = 0.564, P < 0.0001)
in patients.
CSF and serum NfL correlation with DTI
measures
TBSS analysis revealed significant (PFWE < 0.05, cor-
rected for age) negative correlation between NfL mea-
sures and FA (co-localized with positive RD correlation)
in both CSTs in ALS patients (Fig. 2A). Similarly in the
larger serum cohort, NfL levels correlated negatively
with FA (and positively with RD) in both CSTs (Fig.
S1A). In addition, serum NfL levels correlated signifi-
cantly with axial diffusivity in a small region in the
right SLF in patients (Fig. S1B). In the healthy control
group, only a positive correlation between CSF NfL (but
not serum NfL) concentration and RD for a small
region in the left SLF was observed (Fig. 2B). Fig-
ure 3A–D depicts the relationship between CSF NfL
concentrations and the respective DTI measure for the
significant TBSS correlations in the patient group (DTI
indices were averaged across the entire region of the
skeleton in which a significant correlation was observed
(“significant mask”) to generate a single value for illus-
trative purposes).
Discussion
CSF NfL and ALS pathophysiology
The significantly elevated CSF NfL concentrations in the
ALS patients are consistent with previous studies that
reported elevated CSF NfL levels in ALS compared with
healthy and disease controls.2–4 CSF NfL concentrations
have also been noted to be higher in ALS patients with
faster progression rates.5,6 In ALS, it is established that
there is a selective loss of large myelinated axons in the
CST of ALS patients.14 Markedly elevated CSF NfL levels
in ALS may be explained by the higher content of axonal
proteins in motor neurons compared to other neuronal
populations.15 A strong DTI white matter signature
involving the CSTs has been consistently identified in
ALS,9,16 with FA in the CST, in particular the posterior
limb of the internal capsule (PLIC), linked to progression
rate.10,17 While the patients and healthy controls included
in the present studies were not matched for age or gen-
der, group comparisons of NfL levels for an age-matched
subset of participants led to qualitatively similar results,
and we are not aware of any reports highlighting gender
differences in CSF NfL concentrations. Taken together,
we believe our observations reflect the release of NfL into
Figure 1. Scatterplots of CSF NfL concentration and UMN score (A) and progression rate (B) in the ALS patients. CSF, cerebrospinal fluid; NfL,
neurofilament light chain protein; UMN, upper motor neuron; ALS, amyotrophic lateral sclerosis.
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the CSF from the degenerating CSTs in particular due to
the abundance of neurofilaments in large axons and the
highly soluble nature of NfL.18 There is undoubtedly a
contribution from the concurrent degeneration of the
CST within the spinal cord in ALS, which was not cap-
tured by the DTI in this study. The number of patients
and controls with paired CSF NfL and MRI data in the
BioMOx cohort was limited by the practical challenges of
obtaining combined markers in disabled patients and the
invasive nature of CSF extraction in terms of recruitment.
However, the qualitatively similar results obtained with
serum NfL from a larger patient group support the con-
clusions drawn, despite being potentially influenced by
degeneration of peripheral motor axons.
CSF NfL in other disorders
CSF NfL is not a specific marker for ALS. Elevated levels
have been reported in spinal cord injury19 as well as other
neurodegenerative disorders,12 specifically FTD.20,21, Alz-
heimer’s disease (AD),22 and Parkinsonian disorders.23
Few studies have attempted to link NfL and MRI mea-
sures, however. Higher concentrations of NfL were related
to more pronounced white matter changes based on T2-
and proton density-weighted scans in subjects with AD,
subcortical vascular dementia and healthy controls.24
Baseline CSF NfL concentration predicted localized FA
differences in the middle temporal gyrus white matter in
adults at risk for AD.25 Only antibodies to NfL (rather
than measured NfL levels) were linked to MRI markers of
axonal loss in multiple sclerosis (MS).26
DTI and CSF NfL
The core cerebral white matter DTI signature in ALS
involves the CSTs, confirmed across many patient
cohorts.27 We observed CSF NfL correlations in the CSTs
for FA, and RD in particular, but not axial diffusivity
Figure 2. Significant TBSS correlations between CSF NfL concentration and DTI measures in the ALS (A) and in the control (B) group. TBSS results
are overlaid onto the intersection of the skeleton with the respective ROI (green) and the group’s mean FA image (greyscale). TBSS, tract-based
spatial statistics; CSF, cerebrospinal fluid; NfL, neurofilament light chain protein; DTI, diffusion tensor imaging; ALS, amyotrophic lateral sclerosis;
ROI, region-of-interest; RD, radial diffusivity; FA, fractional anisotropy; MD, mean diffusivity; P, posterior; A, anterior; R, right; L, left. x, y, z = MNI
coordinates.
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(L1). RD may be sensitive to Wallerian-type myelin degen-
eration,28 as noted in ALS. Independent MRI or CSF mea-
sures of myelin content in ALS would be desirable to
unravel the precise origins of NfL in the CSF. We have
previously studied myelin integrity using a novel MRI
sequence sensitive to water pools within myelin and
intra- and extra-cellular spaces, known as Multi-compo-
nent Driven Equilibrium Single Pulse Observation of T1
and T2 (mcDESPOT).29 However there were insufficient
BioMOx subjects with both mcDESPOT and CSF or
serum NfL measurements to carry out an analysis of their
relationship.
Lower CSF NfL levels have been noted in patients with
ALS linked to superoxide dismutase (SOD1) mutations
compared to cases with wild-type SOD1.30 Independent
studies in a group of consistently slowly progressive
familial ALS patients homozygous for the SOD1 “D90A”
mutation showed a curious relative sparing (in DTI
terms) of CST involvement compared with sporadic ALS
patients matched for disability and clinical UMN involve-
ment.31 These two findings suggest that CSF NfL levels
(and DTI measures) may be significantly influenced by
genotype. Our study population was uniformly apparently
sporadic, but future studies should also consider potential
genotype effects.
In conclusion, elevated CSF NfL concentrations (and
the highly correlated serum levels) found in ALS appear
to be related to white matter damage within the CSTs as
assessed by metrics derived from DTI. This provides fur-
ther support for NfL as a meaningful biomarker in ALS.
Prospective studies in those suspected to have ALS, in
established ALS mimic disorders, and in those presymp-
tomatic individuals carrying genetic mutations placing
them at high risk of ALS, are now underway to fully
explore the biomarker potential of combined neurochemi-
cal and MRI measures.
Figure 3. Scatterplots illustrating the relationship between CSF NfL concentration and DTI measures in the patient group: FA in the left (A) and
right (B) CST; RD in the left (C) and right (D) CST. CSF, cerebrospinal fluid; NfL, neurofilament light chain protein; DTI, diffusion tensor imaging;
CST, corticospinal tract; FA, fractional anisotropy; RD, radial diffusivity.
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Figure S1. Significant TBSS correlations between serum
NfL concentration and DTI measures in the ALS group:
(A) CSTs, (B) right SLF. TBSS results are overlaid onto
the intersection of the skeleton with the respective ROI,
green) and the group’s mean FA image (greyscale). MD,
mean diffusivity; FA, fractional anisotropy; L1, axial diffu-
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